PERINDOPRIL ( DrugBank: Perindopril )


4 diseases
告示番号疾患名(ページ内リンク)臨床試験数
58肥大型心筋症1
113筋ジストロフィー2
167マルファン症候群3
222一次性ネフローゼ症候群1

58. 肥大型心筋症


臨床試験数 : 126 薬物数 : 135 - (DrugBank : 42) / 標的遺伝子数 : 46 - 標的パスウェイ数 : 162
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2015-004317-24-IT
(EUCTR)
22/06/201709/09/2021A pilot-study to assess Coronary Flow reserve and post-vasodilation Myocardial Blood Flow , measured by PET with 13N-Ammonia, before and after a six-month long treatment with the ACE-Inhibitor Perindopril, in patients with moderate and high-risk Hypertrophic CardiomyopathyA pilot study to assess Coronary Flow Reserve and post-vasodilatatory Myocardial Blood Flow (post-Dipi gMBF), measured by 13N-NH3 PET/CT, before and after a six months-long treatment with the ACE-inhibitor Perindopril, in moderate and high-risk HCM patients”A multicentric, interventional, open label, perspective-design, single-arm, pilot” clinical Study. - CARAPaCe (CoronAry Reserve After Perindopril in hypertophic Cardiomyopathy) Hypertrophic Cardiomyopathy (primitive)
MedDRA version: 20.0;Level: PT;Classification code 10020871;Term: Hypertrophic cardiomyopathy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Trade Name: PROCAPTAN - 10 MG COMPRESSE RIVESTITE CON FILM 60 COMPRESSE IN CONTENITORE PER COMPRESSE PP
Product Name: procaptan
INN or Proposed INN: PERINDOPRIL ARGININA
Other descriptive name: perindopril arginine
Trade Name: PROCAPTAN - 5 MG COMPRESSE RIVESTITE CON FILM 10 COMPRESSE IN CONTENITORE PER COMPRESSE PP
Product Name: procaptan
INN or Proposed INN: PERINDOPRIL ARGININA
Other descriptive name: perindopril arginine
AZIENDA OSPEDALIERO-UNIVERSITARIA CAREGGINULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
21Phase 2Italy

113. 筋ジストロフィー


臨床試験数 : 646 薬物数 : 471 - (DrugBank : 105) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 170
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR2000032525
2020-05-012020-05-01Early intervention for subclinical myocardial prevention of ACEI and beta-blocker in patients with Duchenne muscular dystrophy: a prospective multicenter randomized controlled clinical trialEarly intervention for subclinical myocardial prevention of ACEI and beta-blocker in patients with Duchenne muscular dystrophy: a prospective multicenter randomized controlled clinical trial Duchenne muscular dystrophyGroup A:Perindopril;Group B:metoprolol;Group C:Perindopril and metoprolol;West China Second University Hospital, Sichuan UniversityNULLRecruiting118MaleGroup A:106;Group B:106;Group C:106;Phase 4China
2EUCTR2007-005932-10-GB
(EUCTR)
30/03/200914/04/2009A double-blind randomised multi-centre, placebo-controlled trial of combined ACE-inhibitor and beta-blocker therapy in preventing the development of cardiomyopathy in genetically characterised males with DMD without echo-detectable left ventricular dysfunction - DMD-Heart ProtectionA double-blind randomised multi-centre, placebo-controlled trial of combined ACE-inhibitor and beta-blocker therapy in preventing the development of cardiomyopathy in genetically characterised males with DMD without echo-detectable left ventricular dysfunction - DMD-Heart Protection Duchenne muscular dystrophy
MedDRA version: 9.1;Level: LLT;Classification code 10013801;Term: Duchenne muscular dystrophy
Trade Name: Perindopril 2mg Tablets
Product Name: Perindopril
Trade Name: Cardicor (Merck brand)
Product Name: Bisoprolol
Newcastle upon Tyne Hospitals NHS Foundation TrustNULLNot Recruiting Female: no
Male: yes
140 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): noUnited Kingdom

167. マルファン症候群


臨床試験数 : 21 薬物数 : 40 - (DrugBank : 11) / 標的遺伝子数 : 10 - 標的パスウェイ数 : 50
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01295047
(ClinicalTrials.gov)
July 200611/2/2011Comparison of Medical Therapies in Marfan Syndrome.Effects of Atenolol, Perindopril and Verapamil on Haemodynamic and Vascular Function in Marfan Syndrome - A Randomised Double-Blind Crossover TrialMarfan SyndromeDrug: Atenolol;Drug: VERAPAMIL;Drug: PerindoprilCardiff UniversityNULLCompleted16 Years60 YearsBoth18Phase 4United Kingdom
2EUCTR2005-000749-13-GB
(EUCTR)
30/07/200520/06/2005 A Randomised Double-Blind Trial of Medical Treatment In Marfan Syndrome. A Randomised Double-Blind Trial of Medical Treatment In Marfan Syndrome. Marfan SyndromeTrade Name: Atenolol
Product Name: Atenolol
Product Code: N/A
INN or Proposed INN: N/A
Other descriptive name: N/A
Trade Name: Coversyl
Product Name: Coversyl
Product Code: N/A
INN or Proposed INN: N/A
Other descriptive name: PERINDOPRIL
Trade Name: Verapamil
Product Name: Verapamil SR
Product Code: N/A
INN or Proposed INN: N/A
Other descriptive name: N/A
Cardiff UniversityNULLNot Recruiting Female: yes
Male: yes
60 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yesUnited Kingdom
3NCT00485368
(ClinicalTrials.gov)
January 200411/6/2007Angiotensin Converting Enzyme Inhibitors in Marfan SyndromeThe Effect of an Angiotensin Converting Enzyme Inhibitor on Aortic Wall Properties in Patients With Marfan Syndrome.Marfan SyndromeDrug: Coversyl (perindopril)Bayside HealthBaker Heart Research Institute;The AlfredCompleted18 Years40 YearsBoth17Phase 3NULL

222. 一次性ネフローゼ症候群


臨床試験数 : 310 薬物数 : 295 - (DrugBank : 117) / 標的遺伝子数 : 63 - 標的パスウェイ数 : 194
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR1900021757
2019-03-012019-03-08A randomized controlled trial for hydroxychloroquine sulfate in the treatment of idiopathic membranous nephropathyThe efficacy and safety of hydroxychloroquine sulfate in idiopathic membranous nephropathy: A randomized, controlled, Single-center clinical trial Idiopathic Membranous NephropathyGroup 1:Supportive treatment+Perindopril 8 mg/day;Group 2:Supportive treatment+Perindopril 8 mg/day+hydroxychloroquine sulfate (200mg 2/d);Group 3:Low dose glucocorticoid (0.5mg/kg.d)+cyclosporine A (valley concentration controlled at 50-100ng/ml);Group 4:Low dose glucocorticoid (0.5mg/kg.d)+cyclosporine A (valley concentration controlled at 50-100ng/ml)+hydroxychloroquine sulfate (200mg 2/d);Nephrology Division, First Hospital Affiliated to Army Medical UniversityNULLRecruiting1860BothGroup 1:55;Group 2:55;Group 3:55;Group 4:55;Phase 4China